Abstract
Objective
Study design
Results
Conclusions
Implications
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionReferences
- Clinical characteristics of chronic back pain as a function of gender and oral opioid use.Spine. 2003; 28: 143-150
- Sex, gender, and pain: a review of recent clinical and experimental findings.J Pain. 2009; 10: 447-485
- Opioid prescription claims among women of reproductive age — United States, 2008–2012.MMWR Morb Mortal Wkly Rep. 2015; 64: 37-41
- Increase in prescription opioid use during pregnancy among Medicaid-enrolled women.Obstet Gynecol. 2014; 123: 997-1002
- Patterns of opioid utilization in pregnancy in a large cohort of commercial insurance beneficiaries in the United States.Anesthesiology. 2014; 120: 1216-1224
- Periconceptional use of opioids and the risk of neural tube defects.Obstet Gynaecol. 2013; 122: 838-844
- Maternal treatment with opioid analgesics and risk for birth defects.Am J Obstet Gynecol. 2011; 204: 314.e1-314.e11
- Neonatal abstinence syndrome and associated health care expenditures: United States, 2000–2009.JAMA. 2012; 307: 1934-1940
- The economic burden of neonatal abstinence syndrome in the United States.Addiction. 2017; 112: 1590-1599
- CDC guideline for prescribing opioids for chronic pain — United States, 2016.JAMA. 2016; 315: 1624-1645
- Contraceptive use and method choice among women with opioid and other substance use disorders: a systematic review.Prev Med. 2015; 80: 23-31
- Current contraceptive status among women aged 15–44: United States, 2011–2013.in: NCHS data brief, no 173. National Center for Health Statistics, Hyattsville, MD2014
- Committee opinion no. 642: increasing access to contraceptive implants and intrauterine devices to reduce unintended pregnancy.Obstet Gynecol. 2015; 126: e44-e48
- Improving access to long-acting contraceptive methods and reducing unplanned pregnancy among women with substance use disorders.Subst Abus. 2016; 10: 27-33
Article info
Publication history
Footnotes
☆Funding Support: This work was supported by the University of Arkansas for Medical Sciences Translational Research Institute (grants UL1TR000039 and KL2TR000063) through the NIH National Center for Research Resources and the National Center for Advancing Translational Sciences. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funding source has no involvement in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
☆☆Declaration of interest: Dr. Ray-Griffith currently receives clinical trial support from Neuronetics and has received clinical trial support from Sage Therapeutics. Dr. Stowe has received research support from and consulted for GlaxoSmithKline, Pfizer and Wyeth Corporations, and received speakers' honoraria from the companies plus from Eli Lilly and Forest Corporations prior to 2008. Dr. Stowe received clinical trial support from Janssen Pharmaceuticals and Sage Therapeutics in the past 24 months. Dr. Martin receives royalties and honorarium from TrestleTree LLC for the licensing and presentation of an opioid risk prediction tool. For the remaining authors, none were declared.
